Jiqiang Lin
About Jiqiang
Jiqiang focuses his practice on the representation of public and private pharmaceutical, biotechnology, and other life sciences companies with respect to a variety of intellectual property-based commercial transactions. He advises companies on license agreements, research collaborations and development agreements, manufacturing, distribution, and supply agreements, as well as intellectual property matters within corporate transactions such as public offerings and mergers and acquisitions.
Experience
-
Adverum to Be Acquired by Lilly
-
Hengrui Pharma and GSK Enter Agreement to Develop up to 12 Medicines
-
Inmagene Biopharmaceuticals Completes Merger With Ikena Oncology [UPDATED]
-
Sirius Therapeutics Announces Collaboration With CRISPR Therapeutics
-
Hengrui Pharmaceuticals Announces License Agreement With Merck KGaA
Admissions and credentials
- New York
Rankings and accolades
LMG Life Sciences: Rising Star – Licensing & Collaboration (2025)
Get In Touch
Location
This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.